Evaluation of the Added Value of Sophrology on the Intensity of Craving During Smoking Withdrawal (SOPHCIG)

March 27, 2024 updated by: Centre Hospitalier Intercommunal Creteil
To evaluate the added value of Sophrology on the intensity of craving during cigarette withdrawal.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Pilot study to evaluate the impact of sophrology on the intensity of craving and on certain determinants of cigarette consumption: number of cigarettes, anxiety, degree of dependence, motivation, confidence, fatigue, irritability, quality of sleep.

This pilot study could serve as a basis for the development of research on a larger cohort.

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Créteil, France, 94000
        • Recruiting
        • CHI Créteil Equipe de liaison et de soins en addictologie (ELSA)
        • Contact:
      • Créteil, France, 94000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • First outpatient consultation in tobacco addiction department
  • Consumption greater than or equal to 35 cigarettes per week
  • Minimum age: 18 years old / Maximum age: 75 years old
  • Absence of co-addiction of alcohol, other products and behavioural addictions (except if withdrawal for more than 1 year)
  • Commitment by the patient not to practice hypnosis or mindfulness while participating in the study
  • Mastering reading and writing skills
  • Acceptance to participate in the protocol
  • Affiliated to a social security system

Exclusion Criteria:

  • Patient-reported psychosis
  • Pregnant women
  • Participation in other intervention research
  • Patient under guardianship or curatorship
  • Refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sophrology
the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
No Intervention: Control
the patient must make 7 visits with interviews and questionnaires

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FTCQ-12 questionnaire (French Tobacco Craving Questionnaire - 12 items) (0 to 84)
Time Frame: 6 months after the end of consultations
Comparison of the inte craving between the sophrology group and the control group at nsity of 6 months after the end of consultations, using the FTCQ-12 questionnaire.
6 months after the end of consultations

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of cigarettes smoked per day
Time Frame: 6 months after the end of consultations
Number of cigarettes smoked per day
6 months after the end of consultations
Motivation to Quit Smoking by Numerical Scale (0 to 5)
Time Frame: 6 months after the end of consultations
Assessment of Motivation to Quit Smoking
6 months after the end of consultations
Measuring Confidence in Withdrawal Success by numerical scale (0 to 5)
Time Frame: 6 months after the end of consultations
Measuring Confidence in Withdrawal Success
6 months after the end of consultations
Evaluation of sleep by numerical scale (0 to 5)
Time Frame: 6 months after the end of consultations
Evaluation of sleep quality
6 months after the end of consultations
Evaluation of irritability by numerical scale (0 to 5)
Time Frame: 6 months after the end of consultations
Evaluation of irritability levels
6 months after the end of consultations
Fatigue levels by numerical scale (0 to 5)
Time Frame: 6 months after the end of consultations
Evaluation of fatigue levels
6 months after the end of consultations
Fagerström test (0 to 11)
Time Frame: 6 months after the end of consultations
Comparison of dependency
6 months after the end of consultations
CO (carbon monoxide) test
Time Frame: 6 months after the end of consultations
Comparison of the evolution of the CO
6 months after the end of consultations

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sylvie Ané, Centre Hospitalier Intercommunal Creteil

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 23, 2021

Primary Completion (Estimated)

December 23, 2024

Study Completion (Estimated)

December 23, 2025

Study Registration Dates

First Submitted

November 27, 2020

First Submitted That Met QC Criteria

January 6, 2021

First Posted (Actual)

January 7, 2021

Study Record Updates

Last Update Posted (Actual)

March 28, 2024

Last Update Submitted That Met QC Criteria

March 27, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SOPHCIG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Craving

Clinical Trials on Sophrology

3
Subscribe